KRAS inhibitor
Amgenās Lumakras flunks FDA expert meeting, but market withdrawal looks unlikely for now
Anika Sharma
Amgen’s groundbreaking KRAS inhibitor, Lumakras, faced a pivotal moment as the FDA’s Oncologic Drugs Advisory Committee (ODAC) convened to evaluate ...
Roche’s Latest KRAS Data Shows Promise Against Amgen and Mirati, Yet Verdict Remains Uncertain
Anika Sharma
Roche has presented compelling new data showcasing its KRAS inhibitor, divarasib, as a potential contender against rivals Amgen and Mirati. ...
FDA Convenes Advisors to Assess Full Approval Prospects for Amgen’s Lumakras Amid KRAS Uncertainties
Anika Sharma
Amgen faces a critical juncture with its pioneering KRAS inhibitor, Lumakras, as uncertainties loom over its potential combinability with standard ...
Mirati’s KRAS Inhibitor Krazati Faces Rejection in Europe
SG Tylor
Source – Mirati Therapeutics Mirati Therapeutics has faced a setback in its quest to market its lead KRAS inhibitor Krazati, ...
